Giant Biogene Holding Co. Ltd. Annual Results: Standalone & Consolidated Reports

Annual Results

Results Snapshot

Figures in Million

Consolidate Annual Results

Dec'25

Dec'24

Dec'23

Dec'22

Dec'21

Dec'20

Dec'19

Net Sales

5,984.96

6,005.31

3,894.17

2,749.56

1,871.07

1,337.73

1,084.82

Other Operating Income

0.00

Total Operating income

5,984.96

6,005.31

3,894.17

2,749.56

1,871.07

1,337.73

1,084.82

Raw Material Cost

1,176.88

1,075.44

637.59

429.34

257.13

220.78

193.82

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

406.64

354.92

176.02

138.88

87.84

41.59

32.31

Power Cost

0.00

Manufacturing Expenses

0.33

0.26

0.12

0.02

0.00

Selling and Distribution Expenses

2,411.74

2,340.70

1,392.81

950.59

486.66

198.04

127.18

Other Expenses

-31.07

-23.97

-9.33

-8.77

-6.14

-2.92

-2.02

Total Expenditure (Excl Depreciation)

3,684.92

3,531.61

2,113.24

1,431.14

770.23

431.19

333.14

Operating Profit (PBDIT) excl Other Income

2300

2473.7

1780.9

1318.4

1100.8

906.5

751.7

Other Income

184.80

148.30

115.10

61.53

57.69

15.41

28.68

Operating Profit (PBDIT)

2,574.03

2,675.66

1,933.80

1,411.52

1,181.99

943.13

799.22

Interest

0.33

0.26

0.12

0.02

0.00

Exceptional Items

54.15

46.91

32.41

-10.34

17.44

173.92

-11.29

Gross Profit (PBDT)

4,808.07

4,929.87

3,256.58

2,320.22

1,613.94

1,116.95

891.00

Depreciation

89.20

53.65

37.76

31.57

26.87

23.43

20.28

Profit Before Tax

2,538.66

2,668.66

1,928.32

1,369.58

1,172.57

1,093.63

767.66

Tax

472.46

429.38

328.06

204.86

174.50

164.91

115.45

Provisions and contingencies

0.00

Profit After Tax

2,076.68

2,236.05

1,604.18

1,165.23

998.07

928.68

626.22

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

2,076.68

2,236.05

1,604.18

1,165.23

998.07

928.68

626.22

Share in Profit of Associates

0.00

Minority Interest

-0.19

-0.67

-3.92

-0.51

0.00

0.04

25.99

Other related items

0.00

Consolidated Net Profit

2,076.50

2,235.37

1,600.26

1,164.72

998.07

928.72

652.21

Equity Capital

0.00

Face Value

0.0

Reserves

11,039.54

7,564.65

4,802.74

3,181.25

1,243.80

543.03

1,283.81

Earnings per share (EPS)

1.96

2.23

1.63

0.83

1.0

0.95

0.64

Diluted Earnings per share

1.96

2.23

1.63

0.83

1.0

0.95

0.64

Operating Profit Margin (Excl OI)

38.43%

41.19%

45.73%

47.95%

58.65%

67.6%

69.16%

Gross Profit Margin

43.91%

45.33%

50.49%

50.96%

64.1%

83.5%

72.63%

PAT Margin

34.7%

37.23%

41.19%

42.38%

53.34%

69.42%

57.73%

Public Share Holdings (%)

0.0%

Pledged Promotor Holding (%)

0.0%

Annual Analysis Highlights

Net Sales

YoY Growth in year ended Dec 2025 is -0.34% vs 54.21% in Dec 2024

Consolidate Net Profit

YoY Growth in year ended Dec 2025 is -7.11% vs 39.69% in Dec 2024

Operating Profit (PBDIT) excl Other Income

YoY Growth in year ended Dec 2025 is -5.47% vs 38.97% in Dec 2024

Interest

YoY Growth in year ended Dec 2025 is 0.00% vs 200.00% in Dec 2024

Operating Profit Margin (Excl OI)

YoY Growth in year ended Dec 2025 has fallen from Dec 2024

Compare Annual Results Of Giant Biogene Holding Co. Ltd. With

Select Peers

Figures in Million

Consolidate Annual Results

Change(HKD)

Change(%)

Net Sales

5,984.96

17,401.97

-11,417.01

-65.61%

Other Operating Income

0.00

Total Operating income

5,984.96

17,401.97

-11,417.01

-65.61%

Raw Material Cost

1,176.88

4,607.51

-3,430.63

-74.46%

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

406.64

4,101.82

-3,695.18

-90.09%

Power Cost

0.00

Manufacturing Expenses

0.33

166.39

-166.06

-99.80%

Selling and Distribution Expenses

2,411.74

9,834.07

-7,422.33

-75.48%

Other Expenses

-31.07

-408.97

377.90

92.40%

Total Expenditure (Excl Depreciation)

3,684.92

14,620.09

-10,935.17

-74.80%

Operating Profit (PBDIT) excl Other Income

2,300.04

2,781.88

-481.84

-17.32%

Other Income

184.80

-124.19

308.99

248.80%

Operating Profit (PBDIT)

2,574.03

3,945.01

-1,370.98

-34.75%

Interest

0.33

166.39

-166.06

-99.80%

Exceptional Items

54.15

-891.82

945.97

106.07%

Gross Profit (PBDT)

4,808.07

12,794.46

-7,986.39

-62.42%

Depreciation

89.20

1,287.32

-1,198.12

-93.07%

Profit Before Tax

2,538.66

1,599.48

939.18

58.72%

Tax

472.46

500.73

-28.27

-5.65%

Provisions and contingencies

0.00

Profit After Tax

2,076.68

938.38

1,138.30

121.30%

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

2,076.68

938.38

1,138.30

121.30%

Share in Profit of Associates

0.00

Minority Interest

-0.19

25.13

-25.32

-100.76%

Other related items

0.00

Consolidated Net Profit

2,076.50

963.51

1,112.99

115.51%

Equity Capital

0.00

Face Value

0.00

Reserves

11,039.54

9,713.74

1,325.80

13.65%

Earnings per share (EPS)

1.96

0.64

1.32

206.25%

Diluted Earnings per share

1.96

0.64

1.32

206.25%

Operating Profit Margin (Excl OI)

38.43%

15.99%

0.00

22.44%

Gross Profit Margin

43.91%

16.59%

0.00

27.32%

PAT Margin

34.70%

5.39%

0.00

29.31%

Public Share Holdings (%)

0.00

0.00%

Pledged Promotor Holding (%)

0.00

0.00%

Annual - Net Sales

Net Sales 598.50 Million

in Dec 2025

Figures in Million

YoY Growth in year ended Dec 2025 is -0.34% vs 54.21% in Dec 2024

Annual - Consolidate Net Profit

Consolidate Net Profit 207.65 Million

in Dec 2025

Figures in Million

YoY Growth in year ended Dec 2025 is -7.11% vs 39.69% in Dec 2024

Annual - Operating Profit (PBDIT)

Operating Profit (PBDIT) 238.92 Million

in Dec 2025

Figures in Million

YoY Growth in year ended Dec 2025 is -5.47% vs 38.97% in Dec 2024

Annual - Interest

Interest 0.03 Million

in Dec 2025

Figures in Million

YoY Growth in year ended Dec 2025 is 0.00% vs 200.00% in Dec 2024

Annual - Operating Profit Margin (Excl OI)

Operating Profit Margin (Excl OI) 38.43%

in Dec 2025

Figures in %

YoY Growth in year ended Dec 2025 has fallen from Dec 2024